Compare Moderna, Inc. (MRNA) vs Noble Corporation plc (NE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Moderna, Inc. vs Noble Corporation plc — how do they compare? Moderna, Inc. trades at $197.01 (market cap $78.65B), while Noble Corporation plc trades at $40.19 (market cap $6.73B). The key difference: Moderna, Inc. is far larger — about 11.7× Noble Corporation plc's market cap, and Noble Corporation plc pays a 4.74% dividend while Moderna, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Moderna, Inc. for 59 Days and Noble Corporation plc for 26 Days on average.
| MRNA | NE | |
|---|---|---|
Market Cap | $78.65B | $6.73B |
Volume | 37,373,437 | 1,027,635 |
Sector | Health | Energy |
52-Week High | $203.46 | $54.37 |
52-Week Low | $22.36 | $26.70 |
Typical Hold Time | 59 Days | 26 Days |
Enterprise Value | $74.80B | $8.16B |
Dividend Yield | — | 4.74% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Moderna (MRNA) trades at $196.48, up 4.81% with strong technical momentum as it joins the Nasdaq-100 index. Despite recent earnings beats, the company faces fundamental challenges with revenue declining from $18.9B in 2022 to $1.92B in 2025 and negative net income margins exceeding -140%. The stock's 500% rally in 2026 has pushed valuations to elevated levels with P/S ratio of 35.08, creating divergence between technical strength and financial fundamentals.
While Nasdaq inclusion and cancer vaccine pipeline progress offer catalysts, Moderna faces significant execution risks amid declining COVID revenue and high valuation multiples. Analyst consensus remains cautious with only 28% buy ratings and $115.70 price target well below current levels, suggesting limited near-term upside despite technical bullish signals.
Noble Corporation (NE) trades at $40.97, down 1.16% today, with a bearish technical outlook. The stock shows mixed earnings performance with recent misses but maintains positive cash flow. Analyst consensus is divided with a $52 price target suggesting 27% upside. Recent news includes a long-term drilling contract with Tullow in Ghana, extending utilization into 2027.
The outlook remains cautious due to ongoing legal investigations and volatile earnings. While valuation appears reasonable with EV/EBITDA of 8.79, declining revenue and profit margins pose challenges. The dividend provides income support, but investors face execution risks amid mixed analyst sentiment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →About Noble Corporation plc
Noble Corporation plc is a leading offshore drilling contractor for the oil and gas industry. The company owns and operates a high-specification fleet of mobile offshore drilling units, including drillships and semi-submersibles, that are used for exploration and production activities in deepwater and harsh environments worldwide. Noble focuses on providing safe, efficient, and reliable drilling services to major and independent oil and gas companies globally.
Read more on NE →
